Etoposide or watchful waiting after high-dose chemo
Treatments studied
Part of Cancer clinical trials.
This phase 2 study looks at whether taking oral etoposide after high-dose chemotherapy helps people with a certain type of testicular or ovarian cancer avoid relapse. If you qualify, you may be assigned to take the medicine or simply be monitored without additional treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older and agree to share your medical information for the study
- Have non-seminoma germ cell tumor (from biopsy/blood tests), not pure seminoma
- Your cancer must have come back after standard first chemo, then you finished high-dose chemo plus stem cell transplant (for 2 tandem cycles)
- Your tumor marker blood tests (AFP and hCG) must be normal or going down at screening
- You must have recovered from prior side effects to mild level (no worse than “grade 2”) and have blood counts and organ tests within required ranges
- You must be able to start within 16 weeks after your last high-dose chemo dose, and follow birth-control rules if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a maintenance therapy combining zanzalintinib and etoposide after you've completed high-dose chemotherapy and a stem cell transplant for germ cell cancer. The goal is to see if this drug combination helps prevent the cancer from coming back.
This study looks at how to manage germ cell tumors in children and young adults using careful monitoring for some patients and chemotherapy for others. It aims to see whether these approaches can control the cancer while avoiding unnecessary treatment when possible.
This trial tests a second-line high-dose chemotherapy for germ cell tumors that have come back after initial treatment. It may be an option for patients whose cancer progressed after 3–4 cycles of standard platinum-based chemo.
This trial checks whether a specific treatment approach works better for men with higher-risk non-seminomatous germ-cell tumors that have spread. Doctors will use tumor marker changes and where the cancer started (often the chest area) to help guide treatment choices.
This trial tests a combination of two chemotherapy drugs—teniposide and cisplatin—for people who have just been diagnosed with a malignant germ cell tumor in the brain. The goal is to see if this treatment is safe and effective.
This Phase 3 trial compares a faster chemotherapy approach versus the standard schedule for people with intermediate- or poor-risk metastatic germ cell tumors. The goal is to see which schedule works better and is safer enough to use as initial treatment.
Hear when a new Germ Cell Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.